– NETHERLANDS, Venlo – QIAGEN N.V. (NYSE: QGEN | FRA: QIA) today announced a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and Managing Board.
Lawrence Rosen, a member of the QIAGEN Supervisory Board since 2013, was appointed as its new Chairman with immediate effect.
The appointment comes after Dr. Håkan Björklund decided to step down as Chairman and as a member of the Supervisory Board, and will not stand for re-election at the next Annual General Meeting planned for June 2021. Dr. Björklund was appointed as a new Supervisory Board member in March 2017 and as Chairman in June 2018. The number of Supervisory Directors has been reduced to six.
“It has been a pleasure to be part of QIAGEN, a company having a critical role in modern molecular testing,” said Dr. Håkan Björklund. “I wish my colleagues on the Supervisory Board and Managing Board, and above all the more than 5,200 QIAGEN employees who are truly making a difference during this public health crisis, continued success in helping to improve the lives of people around the world.”
About Lawrence Rosen
Mr. Rosen, a U.S. citizen who spent more than 20 years in senior leadership positions in Europe, also serves on the Supervisory Board of Lanxess AG. He was a member of the Board of Management and Chief Financial Officer of Deutsche Post DHL Group in Germany until September 2016. Prior to that, he served as Chief Financial Officer of Fresenius Medical Care AG & Co. KGaA in Germany from 2003 to 2009. Prior to that, he was Senior Vice President and Treasurer for Aventis SA in Strasbourg, France. Between 1984 and 2000, he held various positions at the Aventis predecessor companies Hoechst AG and American Hoechst / Hoechst Celanese Inc.
“As the leadership and composition of the Supervisory Board changes, and also in light of the recent outcome of the proposed acquisition by Thermo Fisher, the Supervisory Board wants to express its full commitment to QIAGEN pursuing a growth strategy focused on execution and greater value creation. We also look forward to working on a long-term basis with the Managing Board members. The contributions of QIAGEN to society have never been more critical due to the unprecedented magnitude of the coronavirus pandemic,” said Mr. Rosen. “On behalf of my colleagues in the Supervisory Board, I would like to thank Dr. Björklund for his contributions to QIAGEN during his time on the Board and wish him all the best in his future endeavors.”
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics and Life Sciences. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide.
For more information: https://www.qiagen.com/us/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.